Jodi M Smith1, Mark A Schnitzler, Sally K Gustafson, Nicholas J Salkowski, Jon J Snyder, Bertram L Kasiske, Ajay K Israni. 1. 1 Department of Pediatrics, University of Washington, Seattle, WA. 2 Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN. 3 Department of Surgery, Saint Louis University School of Medicine, St. Louis, MO. 4 Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN. 5 Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: In December 2014, a new national deceased donor kidney allocation policy was implemented, which allocates kidneys in the top 20% of the kidney donor profile index to candidates in the top 20% of expected survival. We examined the cost implications of this policy change. METHODS: A Markov model was applied to estimate differences in total lifetime cost of care and quality-adjusted life years (QALY). RESULTS: Under the old allocation policy, average lifetime outcomes per listed patient discounted to 2012 US dollars were US $342,799 and 5.42 QALY, yielding US $63,775 per QALY gained. Under the new policy, average lifetime cost was reduced by US $2090 and lifetime QALYs increased by 0.03. Thus, the new policy improved on the old policy by producing more QALYs at lower cost. The present value of total lifetime cost savings from the policy change is estimated to be US $271 million in the first year and US $55 million in subsequent years. The higher transplant rates and allograft survival expected for candidates in the top 20% of expected survival would decrease costs by reducing time on dialysis. Most cost savings are expected to accrue to Medicare, and most increased access to transplant is expected in private payer populations. CONCLUSIONS: The new allocation policy was found to be dominant over the old policy because it increases QALYs at lower cost.
BACKGROUND: In December 2014, a new national deceased donor kidney allocation policy was implemented, which allocates kidneys in the top 20% of the kidney donor profile index to candidates in the top 20% of expected survival. We examined the cost implications of this policy change. METHODS: A Markov model was applied to estimate differences in total lifetime cost of care and quality-adjusted life years (QALY). RESULTS: Under the old allocation policy, average lifetime outcomes per listed patient discounted to 2012 US dollars were US $342,799 and 5.42 QALY, yielding US $63,775 per QALY gained. Under the new policy, average lifetime cost was reduced by US $2090 and lifetime QALYs increased by 0.03. Thus, the new policy improved on the old policy by producing more QALYs at lower cost. The present value of total lifetime cost savings from the policy change is estimated to be US $271 million in the first year and US $55 million in subsequent years. The higher transplant rates and allograft survival expected for candidates in the top 20% of expected survival would decrease costs by reducing time on dialysis. Most cost savings are expected to accrue to Medicare, and most increased access to transplant is expected in private payer populations. CONCLUSIONS: The new allocation policy was found to be dominant over the old policy because it increases QALYs at lower cost.
Authors: Martin Wijkstrom; Hayato Iwase; Wayne Paris; Hidetaka Hara; Mohamed Ezzelarab; David K C Cooper Journal: Kidney Int Date: 2016-12-01 Impact factor: 10.612
Authors: Rachel C Forbes; Irene D Feurer; David LaNeve; Beatrice P Concepcion; Christianna Gamble; Scott A Rega; C Wright Pinson; David Shaffer Journal: Clin Transplant Date: 2018-03-30 Impact factor: 2.863
Authors: Andrew Wang; Juan Carlos Caicedo; Gwen McNatt; Michael Abecassis; Elisa J Gordon Journal: Transplantation Date: 2021-03-01 Impact factor: 5.385
Authors: Bernadette Li; John A Cairns; Rachel J Johnson; Christopher J E Watson; Paul Roderick; Gabriel C Oniscu; Wendy Metcalfe; J Andrew Bradley; Charles R Tomson; Heather Draper; John L Forsythe; Christopher Dudley; Rommel Ravanan Journal: Transplantation Date: 2020-04 Impact factor: 5.385
Authors: Sameera Senanayake; Nicholas Graves; Helen Healy; Keshwar Baboolal; Adrian Barnett; Matthew P Sypek; Sanjeewa Kularatna Journal: BMC Health Serv Res Date: 2020-10-09 Impact factor: 2.655